Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 6, 2024; 12(1): 68-75
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.68
Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure
Kun Liu, Zhen-Hua Li
Kun Liu, Department of Critical Care Medicine, The Third People's Hospital Of Hubei Province, Wuhan 430030, Hubei Province, China
Zhen-Hua Li, Department of Critical Care Medicine, General Hospital of The Yangtze River Shipping, Wuhan Brain Hospital, Wuhan 430015, Hubei Province, China
Co-first authors: Kun Liu and Zhen-Hua Li
Author contributions: Liu K and Li ZH designed the research; Liu K contributed new reagents/analytic tools; Liu K and Li ZH analyzed the data; Liu K and Li ZH wrote the paper. Liu K and Li Z has co-first authors are threefold. First, Liu K and Li ZH designed and conceptualized the study. Second, Liu K and Li ZH participated in discussion development and provided expert guidance. Third, Liu K and Li ZH put in the same effort throughout the study, and in summary, we believe that Li ZH can be tagged as co-first author in our manuscript.
Institutional review board statement: This study protocol was approved by the General Hospital of The Yangtze River Shipping, Wuhan Brain Hospital, and all the families have voluntarily participated in the study and have signed informed consent forms.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declared no conflict of interest existing in this paper.
Data sharing statement: Data generated from this investigation are available upon reasonable quest from the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhen-Hua Li, MM, Chief Doctor, Department of Critical Care Medicine, General Hospital of The Yangtze River Shipping, Wuhan Brain Hospital, No. 5 Huiji Road, Wuhan 430015, Hubei Province, China. zhenh0911@163.com
Received: November 10, 2023
Peer-review started: November 10, 2023
First decision: November 22, 2023
Revised: December 5, 2023
Accepted: December 18, 2023
Article in press: December 18, 2023
Published online: January 6, 2024
Abstract
BACKGROUND

Recent studies on dialysis anticoagulation therapy in patients with renal failure have shown that Nafamostat mesylate, a broad-spectrum potent serine protease inhibitor, has strong anticoagulation and anti-fiber activity.

AIM

To evaluate the efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure.

METHODS

Seventy-five patients with end-stage renal failure who received hemodialysis at our hospital between January 2020 and August 2021 were selected and divided into the observation group (Nafamostat mesylate for injection, n = 33) and control group (heparin sodium injection, n = 32). General patient data, indicators of clinical efficacy, dialyzer hemocoagulation parameters, coagulation function indices, and hemoglobin concentration and platelet count before and after treatment, and the occurrence of adverse reactions after treatment were compared between the two groups.

RESULTS

The two groups showed no significant differences in general patient data (P > 0.05). The post-treatment effectiveness rate in the control group was lower than that in the observation group (P < 0.05). The two groups showed no significant difference in the number of patients in grade I (P > 0.05), while the number of patients in grade 0 was lower in the control group, and the number of patients in grades II and III was higher in the control group (P < 0.05). The post-treatment prothrombin time, activated partial thromboplastin time, thrombin time, and international normalized ratio values in the control group were higher than those in the observation group, while the fibrinogen level in the control group was lower than that in the observation group (P < 0.05). The two groups showed no significant difference in the platelet count and hemoglobin level before and after treatment (P > 0.05). The total number of post-treatment adverse reactions in the observation group was lower than that in the control group (P < 0.05).

CONCLUSION

Treatment of patients showing end-stage renal failure with Nafamostat mesylate can significantly improve therapeutic efficacy and has high safety and clinical value.

Keywords: End-stage renal failure, Nafamostat mesylate, Effectiveness, Safety study, Chronic kidney diseases

Core Tip: End-stage renal disease refers to the terminal stage of the progression of various chronic kidney diseases, such as chronic nephritis, nephrotic syndrome, and tubulointerstitial disease. We aimed to evaluate the efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure. Treatment of patients showing end-stage renal failure with Nafamostat mesylate can significantly improve therapeutic efficacy and has high safety and clinical value.